This was the key line i was looking for in todays...

This was the key line i was looking for in todays Quarterly.....

"Medibio is now planning for commercial opportunities in the USA in anticipation of FDA clearance, expected in August 2020."

That is as good a confirmation of FDA approval you will get from management!

Further we know they are now actively lining up the commercial deals to follow FDA approval next week....

Then we have the submission for European approval about to be submitted. Another massive market along with the USA.

"Furthermore, the Company will shortly be submitting MEBsleep for CE Mark approval, which will allow commercialisation in Europe."

So many positives to take away from today announcement. The other big one was obviously progress with Ilumen.

"Discussions regarding the re-sale and implementation of ilumenTM both in Australia and internationally are well advanced with Compass Group PLC in London; and separately with its Australian subsidiary, following the successful completion of a number of paid pilot programs."

So expect further updates on that front in the near future as well....

Then there is also DXC discussions...

"Discussions are also on-going with DXC regarding a Re-seller Agreement, whereby DXC will promote ilumenTM to its substantial client base."

As if that wasn't enough positive news for one day Management are in discussions with several other Global organisations....

"Medibio are also in varying degrees of discussions with a number of global organisations, including insurers, benefits management and Employee Assistance Providers (EAP’s), who are seen to be key strategic partners."

FDA approval followed by commercial deals = substantial rerate for MEB shareholders.
MC only $16 Million so plenty of room to rerate.....